💊𝗕𝗹𝗼𝗴𝗴𝗲𝗿 #ConnectingInforming #DrugDiscoverytoDrugDelivery 💻𝗩𝗶𝗱𝗲𝗼 𝗖𝗼𝗻𝘁𝗲𝗻𝘁 𝗖𝗿𝗲𝗮𝘁𝗼𝗿 YouTube: RSK Life Science Media 📈𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝘁-LinkedIn/Marketing/Media/Events, Brand Champion
#News: AstraZeneca on Monday morning unveiled its ambitious plan to be one of the fastest growing pharma companies by the end of the decade. In what CEO @Pascal Soriot described as “a new era of growth,” the UK #pharma said it is targeting $80 billion in total revenue by 2023, which is 75% higher than what it raked in last year at $45.8 billion, according to a Monday press release ahead of its Investor Day in Cambridge, UK. While many of AstraZeneca’s pharma peers have set high expectations for certain top products or near-term sales growth, the British drugmaker’s new declaration is bold in both scope and timeline. To reach its goal, AstraZeneca would have to grow by more than 8% every year over seven years — compared to a 5%-7% target separately set by GSK and Johnson & Johnson (which would similarly put it at $80 billion by 2030), or a 5% target set by Novartis. With pandemic-era exceptions, very few drugmakers have managed to bring in $80 billion in pharma sales alone. Read more from.Endpoints News 👇🏽 https://lnkd.in/eBxZAwBn
